Spironolactone plus Hydrochlorothiazide.
Spironolactone and hydrochlorothiazide oral tablets contain:
spironolactone . . . . . . . . . . . . . . . 25 mg
hydrochlorothiazide . . . . . . . . . . . . 25 mg
INDICATIONS AND USAGE
Spironolactone, an ingredient of spironolactone and hydrochlorothiazide, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide should be used only in those conditions described below. Unnecessary use of this drug should be avoided.
Spironolactone and hydrochlorothiazide tablets are contraindicated in patients with anuria, acute
renal insufficiency, significant impairment of renal excretory function, or hyperkalemia, and in
patients who are allergic to thiazide diuretics or to other sulfonamide-derived drugs. Spironolactone
and hydrochlorothiazide may also be contraindicated in acute or severe hepatic failure.
Product displayed may not be actual product available at time of order